ZK-261991 is an orally active VEGFR tyrosine kinase inhibitor with an IC50 of 5 nM for VEGFR2. The high efficacy, including tumour regression in established tumours, combined with its low toxicity recommends ZK 261991 for development as a drug for the therapy of solid tumours also in combination with other chemotherapeutics.